Showing results (111-120 of 154) with videos related to
Sort By:
Pageof 16
Journal of Biomedical Materials Research|November 1, 1982
In vitro retinoid binding and release from a collagen sponge material in a simulated intravaginal environmentR T Dorr, E A Surwit, W Droegemueller, et al.Biochemical Pharmacology|August 10, 2000
Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexonK Dvorakova, C M Payne, M E Tome, et al.Cancer Research|September 15, 1988
In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratiosR T Dorr, K A Bozak, N G Shipp, et al.Cancer Chemotherapy and Pharmacology|August 14, 1999
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesiaA M Lopez, L Wallace, R T Dorr, et al.Journal of the National Cancer Institute|November 1, 1983
A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasiaF L Meyskens, V Graham, M Chvapil, et al.Journal of Medicinal Chemistry|November 26, 1997
1,4-disubstituted anthracene antitumor agentsB S Iyengar, R T Dorr, D S Alberts, et al.Journal of the National Cancer Institute|August 19, 1992
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitroE M Hersh, C R Gschwind, C W Taylor, et al.Life Sciences|January 1, 1996
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical studyR T Dorr, R Lines, N Levine, et al.Investigational New Drugs|December 1, 1988
Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSHR T Dorr, B V Dawson, F al-Obeidi, et al.Anti-Cancer Drugs|April 6, 2001
Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalatorsR T Dorr, J D Liddil, S M Sami, et al.Pageof 16